Congo to start using Johnson & Johnson Ebola vaccine in November
Health authorities in Democratic Republic of Congo will introduce a Johnson&Johnson Ebola vaccine in November in the country's eastern provinces, to counter the current outbreak, they said.
[Deutsche Welle] Authorities in the Democratic Republic of Congo have started using a second vaccine to fight Ebola. The country is struggling to contain what is now the world's second-worst outbreak of the deadly virus on record.
This study provides a better understanding of GP expression and processing in BmN cells, which may lay a foundation for EBOV-GP expression using the BmNPV baculovirus expression system.
Health authorities in eastern Congo have introduced a new Ebola vaccine produced by Johnson&Johnson, aid group MSF said on Thursday, to help combat the world's second-worst outbreak of the virus on record.
The government of the DRC supports use of Janssen ’s vaccine regimen as part of expanded public health response to country’s Ebola outbreak – the second-worst on record
This article highlights the epidemiology, clinical features, diagnosis, management, and prevention of EVD. The emerging diagnostic technologies, rapid viral characterization, geospatial mapping of EVD transmission, and new treatments and vaccines are discussed.
Darwyn Kobasa Ebola virus (EBOV) is a zoonotic pathogen that poses a significant threat to public health, causing sporadic yet devastating outbreaks that have the potential to spread worldwide, as demonstrated during the 2013–2016 West African outbreak. Mouse models of infection are important tools for the development of therapeutics and vaccines. Exposure of immunocompetent mice to clinical isolates of EBOV is nonlethal; consequently, EBOV requires prior adaptation in mice to cause lethal disease. Until now, the only immunocompetent EBOV mouse model was based on the Mayinga variant, which was isolated in 1...
Abstract Ebola virus (EBOV) represents a major concern to global health due to the unpredictable nature of outbreaks. Infection with EBOV can cause a severe viral haemorrhagic fever with no licensed vaccine or treatment, restricting work with live EBOV to Containment/Biosafety Level 4 facilities. Whilst the magnitude of recent outbreaks has provided an impetus for vaccine and antiviral development, establishing the efficacy of candidate vaccine materials relies on EBOV challenge models and advanced human trials should outbreaks occur and where logistics and funding allow. To address these hurdles in vaccine develo...
Nature, Published online: 21 October 2019; doi:10.1038/d41586-019-03197-wThe World Health Organization says that the rate of new infections in the Democratic Republic of the Congo has dropped, as a vaccine moves closer to approval.
New cases are down to 15 a week from a high of 128 in April, but outbreaks are still popping up in remote and dangerous mining areas.
[Vanguard] Health authorities in the Democratic Republic of Congo will introduce a Johnson&Johnson Ebola vaccine in November in the country's eastern provinces, to counter the current outbreak, they said.